Research announcement · Tufts Medicine · 2026-05-04
A second look at a trial in adults with prediabetes linked variation in the vitamin D receptor gene to differences in the trial results.
Tufts researchers revisited the D2d trial, which assigned adults with prediabetes to vitamin D3 or placebo. The original study found no statistically clear reduction in diabetes across all participants. The new analysis asked whether the result varied with the gene for the vitamin D receptor.
For participants with either of two common versions of one genetic marker, the D3 group had a 19% lower estimated risk of developing diabetes than the placebo group. These versions accounted for around seven in ten of the participants studied.
The analysis included 2,098 people with the genetic data needed for the comparison. For those with two copies of the A version of the marker, the estimated diabetes risk was similar with vitamin D3 and placebo, and the range of uncertainty was wide.
